Clinical trials: Combined Pulmonary Fibrosis and Emphysema
Pulmonary Hypertension, Interstitial Lung Disease
Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease
This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil.
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT05572996
- Testing
- Inhaled Treprostinil
- Sponsor
- Ferrer Internacional S.A.
Pulmonary Hypertension, Interstitial Lung Disease
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT02633293
- Testing
- Inhaled Treprostinil
- Where
- 92 sites in United States, Puerto Rico
- Volunteers
- 243 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Interstitial Lung Disease
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT02630316
- Testing
- Inhaled Treprostinil
- Where
- 97 sites in United States, Puerto Rico
- Volunteers
- 326 people
- Sponsor
- United Therapeutics